See the DrugPatentWatch profile for Strensiq
What is Strensiq (asfotase alfa) used for?
Strensiq is a brand of asfotase alfa, a laboratory-made version of the enzyme tissue-nonspecific alkaline phosphatase. It is used to treat X-linked hypophosphatemia (XLH) and, more prominently, hypophosphatasia (including pediatric-onset forms) caused by defective mineralization from low alkaline phosphatase activity. [1]
How does Strensiq work?
Strensiq replaces the missing or deficient alkaline phosphatase activity. By restoring this enzyme function, it helps improve bone mineralization and supports normal skeletal development and growth in people with certain hereditary forms of hypophosphatasia and XLH. [1]
How is Strensiq given?
Strensiq is given as an injection. The dosing schedule and the exact regimen depend on the condition being treated and the patient’s age and weight, as described in prescribing information. [1]
What side effects do patients commonly report?
Injection-site reactions are among the most common adverse effects associated with Strensiq, reflecting that the drug is administered by injection. Other side effects depend on age and overall treatment course and are listed in the medication’s prescribing information. [1]
Who should not use Strensiq (or who needs extra caution)?
Use of Strensiq is guided by the prescribing information, including precautions related to allergy/hypersensitivity and other patient-specific factors. Clinicians also consider whether the diagnosis is the right match for the drug’s intended uses. [1]
How long is treatment usually continued?
Strensiq is typically continued as a long-term therapy when prescribed for inherited bone disorders related to abnormal alkaline phosphatase activity. Duration depends on response, disease course, and clinician judgment. [1]
What should patients ask their clinician before starting?
Patients often want to confirm the exact diagnosis (so Strensiq is appropriate), discuss the injection schedule, review expected benefits versus risks, and ask about management of injection-site reactions and any monitoring plans described in the prescribing information. [1]
---
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=&name=Strensiq